Brammer Bio advancing 3 year, $200m program: 700 employees expected by mid-2019

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/MeePoohyaphoto)
(Image: Getty/MeePoohyaphoto)

Related tags: Brammer Bio, CDMO, Gene therapy, Clinical supply, Viral vector, Manufacturing

Brammer Bio’s three-year, $200m investment program is set to establish more than 30 suites for both clinical and commercial viral vector supply.

Brammer will have 700 employees focused on providing viral vector products to multiple clients by mid-2019, marking an increase from its current staff of 500, and a twofold increase over the past year.

The viral vector contract development and manufacturing organization (CDMO) is expanding its process and analytical development laboratories as well as its quality control laboratories at its Alachua, FL-based facility.

The three-building campus totals 80,000 square feet, with more than 220 staff, and has supplying first-in-human clinical materials for more than 12 years.

According to the company, the site incorporates equipment and design concepts “that are setting the standard for process and analytical development for clinical trials and ultimately commercial scale manufacturing.”

The expansion is expected to be completed by the end of this year and follows a previous investment that doubled​ its clinical capacity at the site in 2017.

Commercial expansion

The CDMO also is increasing the number of commercial suites at its Cambridge, MA facility from seven to 12, supporting up to 2,000-liter suspension and adherent processes.

Construction at the facility – which Brammer acquired from Biogen in January 2017, in addition to a distribution center – will be completed in the first half of 2019.

More than 250 employees operate the facilities, producing multiple vector products in support of late-stage clinical programs leading to commercial supply.

Additionally, Brammer is renovating its second commercial facility in Lexington, MA to include the Pall iCELLis 500 platform. The 50,000 square foot facility was opened in 2016​.

Construction will be completed in the first half of 2019.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more